Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 3/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | GRN | P28799 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7229428 | 1.00 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL5981288 | 1.00 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL2164847 | 1.00 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL5980910 | 1.00 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL1931750 | 0.98 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL1931748 | 0.98 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL3353915 | 0.98 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL7495280 | 0.93 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1OR51E2 | |
| SCHEMBL3346213 | 0.93 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1OR51E2 | |
| SCHEMBL5981459 | 0.89 | ALDH1A1 (0.43) | LTA4HGRNSORT1METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365609-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11780873-B2 | Highly potent multimeric e-selectin antagonists | GLYCOMIMETICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2022224035-A2 | ANTI-GM1 ANTIBODY BINDING COMPOUNDS | POLYNEURON PHARMACEUTICALS AG (CH) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022224035-A2 | ANTI-GM1 ANTIBODY BINDING COMPOUNDS | POLYNEURON PHARMACEUTICALS AG (CH) | 2022-10-27 | — | — | WO | disclosed |
| CN-109790146-B | Pharmaceutical compounds | 阿尔麦克探索有限公司 | 2022-08-23 | — | — | CN | disclosed |
| US-20210323990-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| US-11072625-B2 | Highly potent multimeric e-selectin antagonists | GLYCOMIMETICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20190233458-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20160184339-A1 | Compounds, Compositions and Methods Using E-Selectin Antagonists for Mobilization of Hematopoietic Cells | GLYCOMIMETICS, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-8883720-B2 | Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity | POLYPHOR AG (CH) | 2014-11-11 | — | — | US | disclosed |
| WO-2002057248-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002057249-A1 | CYCLIC 2-CARBONYLAMINOKETONES AS INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| EP-1173170-A4 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1173170-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6277871-B1 | ANTICANCER AGENTS | ABBOTT LABORATORIES | 2001-08-21 | — | — | US | disclosed |
| US-6204293-B1 | INHIBITING POST-TRANSLATIONAL MODIFICATION OF THE ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE, PROTEIN GERANYLGERANYLTRANSFERASE, OR BOTH | UNIVERSITY OF PITTSBURGH | 2001-03-20 | — | — | US | disclosed |
| WO-2000059503-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-1998050031-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
| EP-0535042-B1 | ANGIOTENSIS CONVERTING ENZYME INHIBITORS | FISONS PLC (GB) | 1995-03-29 | — | — | EP | disclosed |
| US-5348978-A | Angiotensin converting enzyme inhibitors | FISONS PLC (GB) | 1994-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323990-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | SELE, SELP, SELPLG | SLC1A3 2639/4885SLC1A2 2921/4885SLC1A1 2253/4885 |
| US-20190233458-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | SELE, SELP, SELPLG | SLC1A3 2639/4885SLC1A2 2921/4885SLC1A1 2253/4885 |
| US-11072625-B2 | Highly potent multimeric e-selectin antagonists | SELE, SELP, SELPLG | SLC1A3 2019/4885SLC1A2 2246/4885SLC1A1 1743/4885 |
| US-11780873-B2 | Highly potent multimeric e-selectin antagonists | SELE, SELP, SELPLG | SLC1A3 2019/4885SLC1A2 2246/4885SLC1A1 1743/4885 |
| US-20230365609-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | SELE, SELP, SELPLG | SLC1A3 2639/4885SLC1A2 2921/4885SLC1A1 2253/4885 |
| US-20160184339-A1 | Compounds, Compositions and Methods Using E-Selectin Antagonists for Mobilization of Hematopoietic Cells | SELE, SELP, SELPLG | SLC1A3 2304/4885SLC1A2 3057/4885SLC1A1 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.